RÉSUMÉ
PURPOSE: Chemotherapy-related amenorrhea (CRA) is a surrogate for ovarian toxicity and associated risk of infertility and premature menopause. Here, we compare CRA rate with paclitaxel (T)-trastuzumab (H) to that with ado-trastuzumab emtansine (T-DM1). METHODS: Patients with T1N0 HER2 + early-stage breast cancer (eBC) enrolled on the ATEMPT trial and were randomized 3:1 to T-DM1 3.6 mg/kg IV every (q) 3 weeks (w) × 17 vs. T 80 mg/m2 with H IV qw × 12 (4 mg/kg load â 2 mg/kg), followed by H (6 mg/kg IV q3w × 13). Enrollees who self-reported as premenopausal were asked to complete menstrual surveys at baseline and every 6-12 months for 60 months. 18-month CRA (no periods reported during prior 6 months on 18-month survey) was the primary endpoint of this analysis. RESULTS: Of 512 ATEMPT enrollees, 123 who began protocol therapy and answered baseline and at least one follow-up menstrual survey were premenopausal at enrollment. 76 had menstrual data available at 18 months without having received a gonadotropin-releasing hormone agonist or undergone hysterectomy and/or oophorectomy. Median age was 45 (range 23-53) among 18 who had received TH and 46 (range 34-54) among 58 who had received T-DM1. The 18-month rate of CRA was 50% after TH and 24% after T-DM1 (p = 0.045). CONCLUSION: Amenorrhea at 18 months was less likely in recipients of adjuvant T-DM1 than TH. Future studies are needed to understand how T-DM1 impacts risk of infertility and permanent menopause, and to assess amenorrhea rates when T-DM1 is administered after standard HER2-directed chemotherapy regimens.
Sujet(s)
Tumeurs du sein , Maitansine , Ado-trastuzumab emtansine/effets indésirables , Adulte , Aménorrhée/induit chimiquement , Aménorrhée/épidémiologie , Protocoles de polychimiothérapie antinéoplasique/effets indésirables , Tumeurs du sein/traitement médicamenteux , Femelle , Humains , Maitansine/effets indésirables , Adulte d'âge moyen , Paclitaxel/effets indésirables , Paclitaxel/usage thérapeutique , Récepteur ErbB-2/génétique , Trastuzumab/effets indésirables , Jeune adulteSujet(s)
Anticorps monoclonaux/administration et posologie , Anticorps monoclonaux/effets indésirables , Anticorps antitumoraux/effets indésirables , Anticoagulants/usage thérapeutique , Hémoglobinurie paroxystique/induit chimiquement , Syndromes myélodysplasiques/traitement médicamenteux , Polyosides/administration et posologie , Thrombose/induit chimiquement , Thrombose/traitement médicamenteux , Alemtuzumab , Anticorps monoclonaux/usage thérapeutique , Anticorps monoclonaux humanisés , Anticorps antitumoraux/usage thérapeutique , Fondaparinux , Hémoglobinurie paroxystique/complications , Humains , Immunosuppresseurs/effets indésirables , Immunosuppresseurs/usage thérapeutique , Mâle , Adulte d'âge moyen , Syndromes myélodysplasiques/complications , Polypharmacie , Récidive , Thrombose/complications , Résultat thérapeutiqueRÉSUMÉ
Epothilones are a new class of antimicrotubule agents currently in clinical trials. Their chemical structures are distinct from taxanes and are more amenable to synthetic modification. Six epothilones have been studied in preclinical and clinical trials: patupilone (epothilone B), ixabepilone (BMS247550), BMS 310705, sagopilone (ZK-EPO), KOS-862 (epothilone D), and KOS-1584. In vitro data have shown increased potency in taxane-sensitive and taxane-resistant cancer cell lines. This enhanced cytotoxic effect has been attributed to epothilone being a poor substrate for p-glycoprotein drug resistance protein and having high affinity to the various beta tubulin isoforms. Phase I clinical data have shown different dose-limiting toxicities for each of the epothilones. These effects are drug specific, dose specific, and schedule of administration specific. While diarrhea and myelosuppression are the dose-limiting toxicities for patupilone and BMS 310705, respectively, neurologic toxicity, as seen with taxanes, is the dose-limiting toxicity of ixabepilone, sagopilone, and KOS-862. In an effort to decrease neurologic toxicity, investigators have modified dosing schedules with limited success. Ixabepilone has the most mature clinical results with published phase II and III data, and regulatory approval for clinical use in the treatment of breast cancer. Ixabepilone has also been combined with other anticancer agents and has regulatory approval in combination with capecitabine for heavily treated breast cancer.